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The inflammasome is an intracellular multi-protein complex that orchestrates the release
of the pro-inflammatory cytokines IL-1β and IL-18, and a form of cell death known
as pyroptosis. Tyrosine phosphorylation of the inflammasome sensors NLRP3, AIM2,
NLRC4, and the adaptor protein, apoptosis-associated speck-like protein (ASC) has
previously been demonstrated to be essential in the regulation of the inflammasome. By
using the pharmacological protein tyrosine phosphatase (PTPase) inhibitor, phenylarsine
oxide (PAO), we have demonstrated that tyrosine dephosphorylation is an essential
step for the activation of the NLRP3 and AIM2 inflammasomes in human and murine
macrophages. We have also shown that PTPase activity is required for ASC nucleation
leading to caspase-1 activation, IL-1β, and IL-18 processing and release, and cell death.
Furthermore, by site-directed mutagenesis of ASC tyrosine residues, we have identified
the phosphorylation of tyrosine Y60 and Y137 of ASC as critical for inflammasome
assembly and function. Therefore, we report that ASC tyrosine dephosphorylation and
phosphorylation are crucial events for inflammasome activation.
Keywords: inflammasome activation, NLRP3, ASC, tyrosine dephosphorylation, tyrosine phosphorylation
INTRODUCTION
The inflammasome is a multiprotein complex comprising of a sensor receptor protein, an adaptor
protein apoptosis associated speck-like protein (ASC) and the cysteine protease caspase-1 that
upon activation leads to the maturation and secretion of IL-1β and IL-18 cytokines, and a form of
inflammatory cell death known as pyroptosis (1). Inflammasome complexes are named according
to the sensor protein engaged by the danger signal. For instance, the NLRP3 inflammasome is
activated by K+ eﬄux caused by a plethora of agonists, while the AIM2 inflammasome is formed
in the presence of viral and bacterial double-stranded DNA (2, 3).
The NLRP3 inflammasome has been widely studied and its constitutive activation is associated
with autoinflammatory diseases caused by gain-of-function mutations in the NLRP3 gene, known
as Cryopyrin associated periodic syndromes (CAPS) (4–7). Overt NLRP3 inflammasome activation
has been shown to be associated with detrimental inflammation in various cancers, Alzheimer’s
disease and obesity (5–7). With such a widespread impact on disease mechanisms, understanding
the regulation of the NLRP3 inflammasome complex is vital in the development of therapies to
alleviate the inflammatory symptoms caused by NLRP3 inflammasome hyper-activation.
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Protein phosphorylation of specific amino acid residues has
been shown to direct inflammasome activation at mainly the
sensor and adaptor protein level (8). It was reported that NLRC4
is phosphorylated at serine 533 by the kinase Protein Kinase C
Delta (PRKCD/PKCδ) following detection of Type III secretion
systems (T3SS) and bacterial flagellin leading to the formation of
the NLRC4 inflammasome (9). Furthermore, it has been shown
that Bruton’s tyrosine kinase (BTK), anaplastic lymphoma kinase
(ALK), and Protein Kinase D (PKD) can phosphorylate NLRP3.
NLRP3 is also dephosphorylated by protein tyrosine phosphatase
non-receptor 22 (PTPN22) at Y861 and protein phosphatase 2A
(PP2A) at S5 leading to its activation (10–13). Similarly, ASC is
also subjected to phosphoryl modifications by kinases, such as
spleen tyrosine kinase (Syk) and c-Jun N-terminal kinase (JNK)
(14), which act on the kinase Pyk2 to phosphorylate murine
ASC at tyrosine 144 (corresponding to human Y146) leading to
ASC nucleation in inflammasome activation (15). In addition,
Iκβ kinase alpha (IKKα) activity has been shown to negatively
regulate the NLRP3, NLRC4, and AIM2 inflammasomes by
interacting with and sequestering ASC to the nucleus. Following
inflammasome agonist detection, the IKKα-ASC interaction is
inhibited by PP2A thus leading to cytosolic translocation of ASC,
which is then able to interact with the receptor proteins (16).
However, the requirement of tyrosine dephosphorylation of
ASC for inflammasome activation needs to be investigated.
We thus assessed the role of protein tyrosine phosphatases
(PTPases) in regulating NLRP3 and AIM2 inflammasomes
using phenylarsine oxide (PAO), a membrane-permeable PTPase
inhibitor that binds to vicinal thiols in the target protein (17).
We found that PAO mediated NLRP3/AIM2 inflammasome
inhibition was due, in part, to the inhibition of ASC tyrosine
dephosphorylation. Furthermore, by site-directed mutagenesis,
we identified the tyrosine ASC residues that are required for
normal inflammasome function. The understanding of the
tyrosine phosphorylation mechanisms underpinning the role
of ASC would be the basis on which to explore tyrosine
phosphorylation targeting therapeutic interventions.
METHODS
Mice
C57BL/6J mice were obtained from the Biological Resource
Center (BRC), Agency for Science, Technology and Research
(A∗STAR), Singapore, and used to isolate bone marrow
progenitors from femurs and tibia for the differentiation in
vitro of mouse macrophages. Mice were maintained under
specific pathogen-free conditions. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee (IACUC) of the BRC (A∗STAR, protocol #0161113)
in compliance with their Guidelines for Animal Experiments.
Cell Culture
Mouse macrophages (BMDMs) were in vitro differentiated from
bone marrow progenitors isolated from femurs and tibia of
C57BL/6J mice cultured for 8 days in complete Iscove’s Modified
Dulbecco’s Medium (IMDM) (10% fetal bovine serum, 1%
penicillin/streptomycin and glutamine) supplemented by 10%
L929-conditioned medium containing M-CSF. Human THP-
1 monocytic cells were differentiated into macrophage-like
cells with phorbol 12-myristate13-acetate (PMA, 100 nM, Sigma
Aldrich) in complete RPMI-1640 (Gibco) overnight (treatment
phase), then followed by 1-day in PMA-free media (resting
phase) and then used for experiments on day 3. HEK293 cells
were cultured in complete Dulbecco’s modified Eagle’s medium
(DMEM) prior to and during transfections.
Inflammasome Activation and
Phosphatase Inhibition
THP-1 macrophages and BMDMs were primed with LPS from
E.coli (1µg/ml, Enzo Life Sciences) for 3 h. To activate the
NLRP3 inflammasome, nigericin (10µM), or monosodium
urate crystals (MSU; 200µg/ml) was added to the cells for 1
and 6 h, respectively. The AIM2 inflammasome was activated
by transfection with poly(dA:dT) (1µg/ml with 1 µl of
Lipofectamine 2000, Invitrogen) for 6 h after a 3-h LPS treatment.
To inhibit protein tyrosine phosphatases, phenylarsine oxide
(PAO, Sigma-Aldrich) was added to the culture the last 30min
of the LPS treatment, and then the inflammasome activator
was added.
Cytokine Measurements
IL-1β, TNF (R&D Systems) and IL-18 (MBL) were
measured in the cell supernatants by ELISA according to
the manufacturer’s instructions.
Cell Death Assay
Lactate dehydrogenase (LDH) levels in cell-free culture
supernatants were assessed using the CytoTox 96 R© Non-
Radioactive Cytotoxicity kit (Promega) according to
manufacturer’s instructions.
Acetone Protein Precipitation
To assess the secretion of processed forms of IL-1β and caspase-1,
the hour-long nigericin treatment (±PAO following signal 1) was
carried out in serum-free media. Equal amounts of the serum-
free media from each condition were collected and individually
precipitated for 1 h at −20◦C in acetone at a 4X volume of the
sample. The precipitated proteins were resuspended in Laemmli
buffer and subjected to western blot analysis.
Disuccinimidyl Suberate (DSS)-Mediated
Cross-Linking
Following cell treatment, disuccinimidyl suberate (DSS)-
mediated protein crosslinking was carried out to assess ASC
oligomerization, as previously described (18).
Western Blot Analysis
Thirty to fifty micrograms (30–50 µg) of lysates (or acetone
precipitated/ DSS-oligomerized protein samples) were incubated
in Laemmli sample buffer for 5min at 100◦C. The denatured
protein samples were separated by SDS-PAGE followed
by protein transfer to PVDF membrane (Millipore). The
membranes were then blocked with 5% milk (or 5% BSA for
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phosphoprotein analysis) in TBS-Tween-20 at room temperature
for 1 h. The blots were then incubated overnight with the
following primary antibodies: anti-ASC (B-3 1:1,000; N-15-R
1:500), anti-pTyr (pY99, 1:1,000), anti-IL-1β (H153, 1:1,000),
anti-caspase-1 (M-20, 1:500), and anti-β-actin (C-4, 1:1,000)
antibodies (all from Santa Cruz); anti-GAPDH antibody
(Millipore-MAB374, 1:1,000) from Millipore. Following
overnight incubation, the membranes were washed and then
incubated in the corresponding Horseradish Peroxidase
(HRP) conjugated secondary antibody (Dako, Millipore) for
1 h at room temperature, followed by a multi-wash step.
Membranes were developed with SupersignalTM West Pico
chemiluminescence detection (Pierce) solution and visualized by
a chemiluminescence imager (Bio-Rad).
Confocal Microscopy
THP-1 macrophages were cultured in chamber microscope slides
at a density of 150,000 per chamber. Following inflammasome
activation, cells were fixed with 2% paraformaldehyde at
room temperature for 10–15min, and permeabilized in
permeabilization buffer (0.1% saponin, 0.2% gelatin, 5 mg/ml
BSA, and 0.02% sodium azide in PBS), followed by three 10-min
washes with PBS. Cells were incubated in blocking solution
(0.01% saponin, 0.2% gelatin, and 5 mg/ml BSA in PBS) for 45–
60min at room temperature under agitation, followed by ASC
labeling with the anti-ASC (SCBT N-15-R, 1:50) antibody for 1 h
at room temperature or overnight at 4◦C. Cells were washed 3
times for 10min each with PBS, and then the secondary anti-
Rabbit Alexa Fluor-488-conjugated antibody (Life Technologies,
1:1,000) was added for 1 h at room temperature on the dark.
Nuclear staining was carried out by adding 4’,6-diamidino-2-
phenylindole (DAPI) on the third wash. The images were taken
with an Olympus confocal microscopy system (FV-1000 inverted
Olympus IX81microscope, magnification of 100X, 2X digital
zoom) and speck count was done using ImageJ software. At
least 7 fields of ≥100 cells were blindly selected and counted
per condition. The nuclei to ASC speck ratio was calculated and
multiplied by 100 to produce a percentage for comparison across
conditions. Statistical analysis was carried out with the two-tailed
paired t-test with Gaussian distribution (parametric test) with
the GraphPad Prism software.
Protein Immunoprecipitation
Lysates (0.5–1.0mg) obtained with complete RIPA buffer
containing 1mM sodium orthovanadate and protease inhibitor
cocktail were initially pre-cleared with protein G sepharose
beads for 1 h at 4◦C. The preclear mix was centrifuged at
maximum speed for 30 s at 4◦C and the supernatant collected,
and the primary anti-pTyr-pY99 (SCBT, cat. sc-7020), anti-ASC
(Adipogen, cat. AL177), and IgG from mouse serum (Sigma
Aldrich, cat. I5381-1MG) antibodies were added. The antibody-
supernatant mix was incubated for 2 h or overnight at 4◦C with
agitation. Protein G coated beads were added to the supernatant-
antibody complex and incubated overnight at 4◦C. Then the mix
was centrifuged, washed twice with complete RIPA buffer, and
incubated with 30–60 µl of Laemmli buffer for 5min at 100◦C
prior to protein separation on SDS-PAGE.
Generation of ASC Mutant Plasmids
Tyrosine to phenylalanine (Y>F) ASC mutants of the pEF6-
ASC-GFP plasmid were generated using the Q5 site-directed
mutagenesis kit (New England Biolabs) according to the
manufacturer’s instructions. The mutated plasmids were
transformed into DH5α chemically competent E. coli and then
isolated by mini- or midi-preps (Qiagen). The isolated plasmids
were then sequenced to validate the mutations.
Transfection of HEK293 Cells
HEK293 cells were seeded into 24 well plates at a cell density
of 200,000 cells per well and incubated overnight. Cells were
then transfected with pCR3-NLRP3-FLAG (100 ng), pEF6-
ASC-GFP and validated mutants (50 ng), pCI-pro-caspase-1
(30 ng, Addgene #41552), pcDNA3-pro-IL-1β (100 ng), and
empty pCR3.1 vector (620 ng) with Lipofectamine 2000 (Life
Technologies) for 24 h. Media was changed and cells incubated
for an additional 24 h. Forty-eight hours later, the media was
collected for ELISA analysis and the lysate prepared for western
blot analysis.
Real-Time RT-PCR
Total RNA was isolated using Trizol R© (Invitrogen) followed
by PureLinkTM RNA Mini Kit (ThermoFisher). Genomic DNA
was removed using a PureLinkTM DNase Set (ThermoFisher).
RNA retrotranscription was performed using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
Semi-quantitative RT-PCR was performed in triplicates using
QuantiFast R© SYBR R© Green PCR kit (Qiagen) and the following
primers: IL-1β forward 5′-CCAGTGAAATGATGGCTT
ATTAC-3′, reverse 5′-CTGTAGTGGTGGTCGGAGATT-3′;
IL-8 forward 5′-CATCTCACTGTGTGTAAACATGAC-3′,
reverse 5′-CCTTGGCAAAACTGCACCTTCAC-3′; GAPDH
forward 5′-CCACATCGCTCAGACACCAT-3′, reverse 5′-GGC
AACAATATCCACTTTACCAGAGT-3′. Amplification was
performed on a ViiA 7 Real-Time PCR System. The relative
expression level of each gene was evaluated by the 2-DDCt
method. The difference between Ct of the target gene and Ct of
the housekeeping gene GAPDHwas normalized to the difference
between the Ct of the same genes in the untreated condition used
as calibrator.
Statistical Analysis
Statistical analysis was carried out using the GraphPad Prism
Software. All ELISA data were analyzed by ordinary One-Way
ANOVA and ASC speck count data was analyzed by two-tailed
paired t-test with Gaussian distribution (parametric test).
RESULTS
PAO Inhibits NLRP3 Inflammasome
Activation
The vital role that tyrosine phosphorylation plays in the
regulation of protein function is indisputable. To assess the role
of tyrosine phosphorylation in the formation and function of
the inflammasome complex we used PAO, a broad-spectrum
PTPase inhibitor (19). PAO has been identified as an inhibitor
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FIGURE 1 | PAO inhibits NLRP3 inflammasome activation. THP-1 macrophages (A,C–E) and BMDMs (B,D) were primed with LPS (1µg/ml) for 3 h followed by
treatment with PAO (0.01–10µM) or vehicle for 30min. Nigericin (10µM) or MSU crystals (200µg/ml) were then added for 1 and 6 h, respectively, to activate the
NLRP3 inflammasome. IL-1β, IL-18, and TNF release was assessed in cell-free supernatants of THP-1 macrophages (A) and BMDMs (B) by ELISA. (C) LDH
measurement was carried out on THP-1 macrophage supernatants to evaluate cell death. (D) Pro-IL-1β level and processing of IL-1β and caspase-1 were assessed
by immunoblot in THP-1 macrophages and BMDMs. (E) Pro-IL-1β and IL-8 transcript levels were measured in THP-1 macrophages by real-time RT-PCR. Data
represent the means ± standard error of three independent experiments. Statistical analysis was carried out by comparing each of the inhibitor treatment conditions
to the LPS+Nig or LPS+MSU condition using ordinary one-way ANOVA with the Dunnett test. *p ≤ 0.05; ***p ≤ 0.001; ****p ≤ 0.0001; ns, p > 0.05.
of protein tyrosine phosphatases by binding to the catalytic site
of the target protein tyrosine phosphatase (17, 20). Human THP-
1 macrophages and mouse bone marrow-derived macrophages
(BMDMs) were primed with LPS for 3 h followed by addition of
increasing concentrations of PAO (0.01–10µM or vehicle) for
30min. Then, cells were stimulated with nigericin (10µM) or
MSU (200µg/ml) to activate the NLRP3 inflammasome. PAO
inhibited IL-1β release by THP-1 macrophages (Figure 1A) and
BMDMs (Figure 1B) in a dose-dependent fashion. Similarly,
nigericin-induced IL-18, but not TNF, release by THP-1
macrophages was also reduced (Figure 1A). Moreover, we found
that PAO also inhibited cell death of THP-1 macrophages
following nigericin stimulation (Figure 1C). The PAO-mediated
inhibition of nigericin-induced cell death occurred at the same
concentration as the inhibition of IL-1β release (Figure 1A).
To further understand whether PAO interferes with
the priming or activation step of NLRP3 inflammasome
activation we examined the pro-caspase-1 and pro-IL-
1β expression, processing and release by western blot.
The cleaved and secreted forms of both caspase-1 (p10)
and IL-1β (p17) were undetectable in the supernatant of
nigericin-activated THP-1 cells and BMDMs in the presence
of PAO (Figure 1D, Supplementary Figures 1A,B). PAO
treatment did not alter pro-IL-1β protein expression (Figure 1D,
Supplementary Figure 1C). Also, mRNA levels of pro-IL-1β and
IL-8 (non-inflammasome cytokine) were unchanged by PAO
compared to vehicle control (Figure 1E). These data indicate
that PAO inhibits NLRP3 inflammasome activation but not the
priming step.
PAO Inhibits ASC Oligomerization and
Speck Formation
ASC speck formation is a hallmark of inflammasome activation.
To investigate whether the effect of PAO is upstream of caspase
activation, we analyzed speck formation in LPS-primed THP-
1 macrophages stimulated with nigericin in the presence or
absence of PAO treatment. ASC specks were readily visible
in nigericin-stimulated THP-1 macrophages and significantly
reduced in the presence of PAO, as assessed by confocal
microscopy (Figures 2A,B).
To further confirm the PAO-mediated disruption of ASC
speck formation, an ASC oligomerization assay was carried out
by DSS-mediated crosslinking. Nigericin treatment led to ASC
oligomerization with the protein mostly existing as a dimer,
whereas ASC oligomerization was attenuated in the presence
of PAO (Figure 2C). These data indicate that PAO acts at
the nucleation step of the ASC filament formation upstream
of caspase-1.
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FIGURE 2 | Inhibition of tyrosine dephosphorylation hinders ASC aggregation.
THP-1 macrophages were primed and treated with PAO (1µM) for 30min.
Nigericin (10µM) was then added for 30–45min. (A,B) Cells were fixed (2%
paraformaldehyde) and immuno-stained with an anti-ASC antibody followed
by anti-rabbit Alexa Fluor-488-conjugated secondary antibody then visualized
by confocal microscopy (Magnification 100X, scale bar 20µm). The number of
THP-1 macrophages containing an ASC speck per nucleus (DAPI stained) was
counted and calculated as a percentage. All data represent the means ±
standard error of a representative experiment out of three. Two-tailed paired
t-test was carried out with Gaussian distribution assumed (parametric test) **p
≤ 0.01. (C) DSS-mediated crosslinking of ASC monomers was carried out
and analyzed by immunoblot. Representative image of n = 3.
PAO Inhibits the AIM2 Inflammasome
We next asked whether PAO could block other inflammasomes.
The AIM2 inflammasome is formed following the detection of
bacterial and viral double-stranded DNA (3). Experimentally,
synthetic double-stranded DNA, poly(deoxyadenylic-deoxy
thymidylicpolyic) [poly(dA:dT)] serves as an activator of
the AIM2 inflammasome (3). Following LPS priming, THP-
1 macrophages and BMDMs were treated with increasing
concentrations of PAO or vehicle followed by cytosolic
transfection of poly(dA:dT) for 6 h. PAO inhibited poly(dA:dT)-
induced IL-1β release by THP-1 macrophages and BMDMs
in a dose-dependent manner, similarly to nigericin and MSU-
mediated NLRP3 inflammasome activation (Figures 3A,B).
Poly(dA:dT)-mediated cell death of THP-1macrophages assessed
as lactate dehydrogenase (LDH) release was also attenuated by
PAO treatment (though not statistically significant) (Figure 3C).
These data indicate that PTPase activity is important for the
activation of NLRP3 and the AIM2 inflammasomes.
Phosphorylation Status of Tyrosines Y60
and Y137 Regulates ASC Function
Nigericin treatment induced a general protein tyrosine
dephosphorylation, which was inhibited by the addition of
PAO, indicating that PAO effectively inhibited protein tyrosine
phosphatase activity (Figure 4A, Supplementary Figures 1D,E).
We next determined the tyrosine phosphorylation status of
ASC in THP-1 macrophages by immunoprecipitation analysis.
We found that ASC was in a state of tyrosine phosphorylation
at the steady state in THP-1 macrophages, and stimulation
by LPS+nigericin induced tyrosine dephosphorylation of
ASC (Figure 4B, Supplementary Figures 1D,E). ASC tyrosine
dephosphorylation was inhibited by the addition of PAO
(Figure 4B, Supplementary Figures 1D,E). Furthermore,
our negative IgG control revealed that there is no non-
specific IgG binding to ASC in the immunoprecipitation
(Figure 4B, Supplementary Figure 1E). This also shows
that there is no non-specific binding of the IgG to pTyr
since ASC, a protein phosphorylated at tyrosine, is not
immunoprecipitated. Therefore, our data suggests that ASC
tyrosine dephosphorylation is a necessary step in NLRP3
inflammasome complex formation and function.
We further investigated ASC tyrosine phosphorylation by
site-directed mutagenesis of the specific tyrosine residues Y36,
Y60, Y137, and Y146 to phenylalanine, a non-phosphorylatable
tyrosine mimic. This Y>F mutation maintains the protein
structure but prevents phosphorylation at the mutated site
because phenylalanine lacks a hydroxyl group required for the
addition of a phosphoryl group. The tyrosine residues of ASC
protein were selected with the following criteria: conservation
between mouse and human and predicted to be phosphorylated
by an online phosphorylation site prediction algorithm
(PhosphoNET: http://www.phosphonet.ca) (Figures 5A,B).
We utilized Y146 as our positive control as it has already been
shown to be required for ASC function (14, 15, 21). Following
mutagenesis of tyrosine to phenylalanine, the wild type and
mutant ASC plasmids were co-transfected into HEK293T cells
along with plasmids encoding human NLRP3, pro-caspase-1
and pro-IL-1β for 48 h. We found that similarly to Y146, Y60,
and Y137 ASC mutants generated exhibited a diminished
inflammasome activity measured by IL-1β release, compared
to the wild type ASC, indicating that Y60 and Y137 residues
require tyrosine phosphorylation for normal ASC function
(Figure 5C, Supplementary Figure 1F). Conversely, the Y36F
ASC mutant does not exhibit reduced functionality (Figure 5C,
Supplementary Figure 1F), indicating that Y36 phosphorylation
is not required.
DISCUSSION
In the present report, using a pharmacological inhibitor
and site-directed mutagenesis we have shown that tyrosine
dephosphorylation of the inflammasome adaptor ASC by
PTPases is a crucial step for the activation of NLRP3 and
AIM2 inflammasomes in human and murine macrophages.
Furthermore, we identified the phosphorylation of tyrosine Y60
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FIGURE 3 | PAO inhibits the AIM2 inflammasome. LPS-primed THP-1 macrophages and BMDMs were transfected with poly(dA:dT) (1 µg/µl) for 6 h in the presence
or absence of increasing doses of PAO (0.01–1µM) or with the vehicle. ELISA was carried out to measure IL-1β release from THP-1 macrophages (A) and BMDMs
(B). (C) LDH measurement was carried out on THP-1 macrophages supernatants to assess cell death. All data represent the means ± standard error of three
experiments. Statistical analysis was carried out by comparing each of the inhibitor treatment conditions to the LPS+Poly(dA:dT) condition using ordinary one-way
ANOVA with the Dunnett test. *p ≤ 0.05; **p ≤ 0.01; ns, p > 0.05.
FIGURE 4 | The nigericin-induced global and ASC tyrosine dephosphorylation
is inhibited by PAO. THP-1 macrophages were primed followed by treatment
with PAO (1µM) for 30min. Nigericin (10µM) was then added for 1 h. (A)
Immunoblot analysis was carried out on total cell lysates for tyrosine
phosphorylation and ASC using anti-pTyr (pY99) and anti-ASC antibodies,
respectively. β-actin was used as a loading control. (B) Immunoprecipitations
of ASC and phosphotyrosine proteins were carried out followed by
immunoblots for pTyr and ASC, respectively. Immunoprecipitation using beads
coated by mouse IgG was performed as negative control. Data is
representative experiment out of three.
and Y137 of ASC as a critical event for inflammasome assembly
and function, including ASC nucleation, caspase-1 activation,
IL-1β, and IL-18 processing and release, and cell death.
This is the first time that PAO has been shown to elicit an effect
on nigericin-induced NLRP3 inflammasome functionality. The
IL-1β mechanism of release has been attributed to the loss of cell
membrane integrity as a consequence of necrotic or pyroptotic
cell death (22, 23). We have shown that inflammasome-induced
cell death is attenuated in the presence of PAO and this might
explain the lack of IL-1β release (due to inhibition of membrane
permeability). Indeed, we showed that pro-IL-1β expression level
is unaltered while the processing is disrupted. Alternatively,
pro-IL-1β processing could be perturbed due to PAO-mediated
attenuation of caspase-1 activation, according to Takahashi et al.
(24). Since caspase-1 activation is dependent onASC aggregation,
analysis of ASC nucleation and speck formation showed that
PAO inhibits ASC oligomerization and formation of ASC specks.
This indicates that the PAO-elicited inhibitory effect is upstream
of caspase-1 processing.
The AIM2 inflammasome, activated by intracellular double
stranded DNA, is formed with the same components as the
NLRP3 inflammasome with exception of the sensor protein.
In our study, treatment with PAO similarly resulted in
attenuation of IL-1β release and cell death in both human and
murine macrophages. This demonstrates that PAO acts upon
a pathway that is common in the regulation of these two
inflammasome complexes.
To further dissect the mechanism involved in PAO-
mediated inflammasome inhibition, we showed that PAO
inhibited nigericin induced global dephosphorylation of
tyrosine residues, implicating the inhibition of some PTPase
activity in inflammasome suppression and suggesting that
tyrosine dephosphorylation is critical for the activation of the
inflammasome. In contrast to PAO, sodium orthovanadate
(OVN), a competitive inhibitor that competes with phosphate
for the catalytic site of PTPases (25), augmented IL-1β release
(26). However, the long treatment durations employed in
this study suggests the observed effects more likely resulted
from gene transcription rather than a direct effect of OVN
on inflammasome activation. In another study, pre-treatment
with OVN (1mM) for 1-h prior to ATP treatment augmented
ATP-induced IL-1β release in murine cells. However, at lower
concentrations, OVN had no impact. Interestingly, Hoyt
and colleagues also showed that while ATP induced global
tyrosine dephosphorylation and IL-1β release, ethanol induced
further global dephosphorylation but blocked IL-1β release.
Furthermore, OVN reversed the ethanol-mediated inhibition of
IL-1β release in a concentration dependent manner, suggesting
that these processes likely occur independently. In this regard,
Hoyt et al. also showed that both the OVN and ATP-induced
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FIGURE 5 | Residues Y60 and Y137 are required for ASC function. (A,B) Tyrosine residue selection criteria were based on conservation of the residues between
mouse and human proteins and predicted by the online predication algorithm phosphoNET to undergo phosphorylative post-translational modifications. (C)
Site-directed mutagenesis of Y36, Y60, Y137, and Y146 to phenylalanine was carried out and the NLRP3 inflammasome was reconstituted in HEK293T cells by
transfection of NLRP3, pro-casp-1, pro-IL-1β, and validated ASC variants. IL-1β ELISA was carried out to measure the function of the reconstituted NLRP3
inflammasome. Representative image of immunoblot analysis of ASC to determine equal transfection (n = 3). GAPDH was used as loading control for the immunoblot.
Statistical analysis was carried out by comparing each of the mutant transfection conditions to the ASC-WT condition using ordinary one-way ANOVA with the
Dunnett test. **p ≤ 0.01, ***p ≤ 0.001.
ASC phosphorylation at Y144 was abrogated by ethanol.
However, the OVN-induced p-ASC at Y144 did not elicit IL-1β
release (21). Put together, the differences observed between PAO
and OVN could be due to differences in protein targets and
mechanisms of action. Whilst there are common targets of OVN
and PAO, there could be PAO-sensitive non-PTPase targets
that are involved in inflammasome activation. For instance, the
non-PTPase NADPH oxidase 2 (NOX2) is inhibited by PAO
(27–29) and has been shown to regulate oxidative stress-induced
NLRP3 inflammasome activation in murine neural tissue (30).
Furthermore, PAO can inhibit non-tyrosine phosphatases, such
as the calcium and calmodulin-dependent serine/threonine
phosphatase calcineurin in the bovine brain (31). In calcineurin
transgenic mice, where calcineurin is constitutively active, the
NLRP3 inflammasome is activated implying that calcineurin
plays an activatory role in NLRP3 inflammasome in myocardial
tissue (32). Another target for PAO is RhoA GTPase (19),
however RhoA has only been reported to be involved in the
pyrin inflammasome (33). Taken together, although NOX2,
calcineurin and RhoA GTPase are PAO-sensitive, inhibition
by PAO does not account for the observed inhibition of both
NLRP3 and AIM2 inflammasomes in our investigation where
human and murine macrophages with concentrations of 1µM
and 0.1µM (respectively) have significantly reduced NLRP3
inflammasome function. In the case of calcineurin, it would
be interesting to assess whether calcineurin is involved in
nigericin-mediated NLRP3 inflammasome function. Since we
observed that ASC tyrosine dephosphorylation is inhibited by
PAO, we hypothesize that PAO acts on a pathway that regulates
tyrosine dephosphorylation of ASC upon inflammasome
activation, thereby implicating one or more PTPases that have a
higher affinity for PAO compared to OVN.
ASC phosphorylation at Y146 (corresponding to Y144 in
mouse) by Pyk2 has been shown to be necessary for ASC
function (14, 15). Our immunoprecipitation data suggests
that ASC is perpetually phosphorylated at tyrosine and
dephosphorylated upon stimulation with nigericin to form
the NLRP3 inflammasome. The phosphorylative regulation of
NLRP3 has already been demonstrated, where an NLRP3
agonist enlists tyrosine kinases (BTK, ALK) (10) and tyrosine
phosphatase PTPN22 (11) to phosphorylate and dephosphorylate
NLRP3 resulting in inflammasome activation. Therefore, since
we have now demonstrated that dephosphorylation of ASC also
takes place, we hypothesize that ASC is regulated by tyrosine
kinases (e.g., Pyk2) and a yet to be identified protein tyrosine
phosphatase upon inflammasome activation leading to ASC
aggregation and speck formation.
The Y144 residue of ASC in mouse is conserved in human
(Y146), which indicates that this residue is required for normal
function. It has previously been demonstrated that mutation
of the Y144/6 residue resulted in the inability of ASC to form
specks (14, 15), therefore, we sought to identify and characterize
putative ASC tyrosine residues. The Y36, Y60 and Y137 residues
were identified and mutated to phenylalanine (F) which mimics
constitutive dephosphorylation and prevents phosphorylation
without much disruption to overall protein structure.We showed
that Y60 and Y137 residues require phosphorylation for optimal
ASC function but not Y36. The Y36F mutant functioned as the
wild type which suggests two possibilities; phosphorylation at
this residue is not required for inflammasome function, or that
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Y36 is phosphorylated in inactivated cells and dephosphorylated
upon activation. Therefore, to further elucidate the regulation
of ASC by phosphorylation, mimicking of constitutive tyrosine
phosphorylation could be carried out to allow the comparison
of the two phosphorylation states on ASC functionality and
thus enable the determination of whether dephosphorylation
or phosphorylation is required for ASC function. However, to
introduce a constitutively phosphorylated tyrosine, a synthesized
(unnatural) phosphotyrosine would need to be incorporated into
the full-length protein at the target site as there is no naturally
occurring pTyr mimic. Although glutamate has been used as a
pTyr mimic (34), it lacks the chemical and structural similarity
to pTyr. This, therefore, means that glutamate substitution
introduces a chemical and structural change to the protein
of interest, thus not recapitulating the intended constitutive
phosphorylation at tyrosine. However, glutamate is better suited
as a mimic for phospho-serine and phosphothreonine (35).
Therefore, synthetic pTyr mimics are the only option and have so
far been incorporated into peptides or by genetic code expansion.
However, these two approaches are both highly undeveloped
to be utilized in full-length proteins (36). Overall, with the
identification of Y60 and Y137 as necessary for inflammasome
function, we have shed more light on how the adaptor protein
is regulated by tyrosine phosphorylation in inflammasome
complex formation.
In conclusion, we have shown that PAO-mediated PTPase
inhibition results in the inhibition of the NLRP3 inflammasome
via, in part, inhibition of ASC tyrosine dephosphorylation.
Our study provides the basis on which to identify the
phosphatase(s) involved in ASC regulation and thus have
a therapeutic target to treat the symptoms of the various
inflammasome-related diseases. We have also identified Y60 and
Y137 as putative tyrosine phosphorylation residues adding to
the understanding of ASC phospho-regulation in inflammasome
complex formation and function.
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